New antibiotic development is economically nonviable: large pharma has exited the space while antimicrobial resistance kills 1.27 million people annually

Large pharmaceutical companies have almost entirely abandoned antibiotic R&D because new antibiotics generate insufficient return on investment compared to chronic-disease drugs, creating a market failure where the drugs most urgently needed to combat antimicrobial resistance (AMR) have no sustainable commercial model. Antibiotic INDs filed by large companies declined from over 75% of the total in the 1980s to under 20% in the 2010s. Why it matters: only 7 new classes of antibiotics have been discovered since 1962 (and only 1 since 1987), so the pipeline consists of mostly incremental modifications rather than novel mechanisms, so drug-resistant infections already kill an estimated 1.27 million people globally per year, so without new classes of antibiotics common medical procedures like surgery, chemotherapy, and organ transplants become life-threateningly risky, so the WHO projects AMR could cause 10 million deaths annually by 2050 and $100 trillion in lost economic output. The structural root cause is that antibiotics are short-course treatments (unlike chronic disease drugs), stewardship programs intentionally restrict their use to preserve efficacy, and widespread cheap generics make it impossible for novel antibiotics to recoup development costs -- creating a paradox where the most medically critical drugs are the least commercially attractive.